The cc-TDI Youth Art & Writing Contest invites K–12 students to showcase their creativity while joining the fight against childhood cancer. Whether through visual art
To Donate to this cause, please click here Throughout Maya’s brave journey, our family found both hope and guidance in cc-TDI’s work, making this cause
This year marks 10 years of innovation and progress at cc-TDI, and we’re proud to reflect on the milestone we’ve reached—because of you. Despite a
We’re celebrating 10 years of impact at cc-TDI! Thanks to your partnership, we’ve translated two drugs into three national and international clinical trials, published 68
The Children’s Cancer Therapy Development Institute (cc-TDI) is proud to announce a new publication, DNA methylation patterns are influenced by Pax3::Foxo1 expression and developmental lineage
This holiday season, we recognize the promise that our research holds for childhood cancer heroes and their families. And at cc-TDI, the parent partnership is
Be part of our team, uncovering how childhood cancers work – and helping find the treatments that could go to clinical trials to improve outcomes.
The Children’s Cancer Therapy Development Institute (cc-TDI) has been awarded $222,120 by the Megan’s Mission Foundation to advance three clinical research initiatives focused on Rhabdomyosarcoma
This month, we invite you to join us in supporting pioneering research at cc-TDI, which has served as a beacon of hope for families like ours. Our
In a groundbreaking study, Entinostat as a combinatorial therapeutic for rhabdomyosarcoma, published earlier this week in Scientific Reports, researchers with the Children’s Cancer Therapy Development
The Children’s Cancer Therapy Development Institute (cc-TDI) is delighted to welcome former Intel Executive, Claire Newman, as their new Executive Director on July 1st. Claire
The Hundt Strong golf outing began in 2017 as a way to support Billy Hundt during his extensive treatment for rhabdomyosarcoma (RMS). From that very
On Monday, May 13th, joined by dear supporters and friends, cc-TDI virtually celebrated the one-year anniversary of our new laboratory. Thanks to incredible support over
In March the Children’s Cancer Therapy Development Institute (cc-TDI) announced its partnership with Team KOODAC (Knock Out Oncogenic Drivers and Curing Childhood Cancer), a global
We are thrilled to present the 2023 inaugural Impact Report for the Children’s Cancer Therapy Development Institute (cc-TDI), a testament to our joint commitment to advancing childhood
We proudly announce our global Artificial Intelligence (AI) collaboration with Atomwise, resulting in a new publication in the journal Scientific Reports. The paper, “AI is
In a significant stride towards advancing pediatric cancer research, we are thrilled to announce that the state of Oregon has allocated a generous $1 million
The Children’s Cancer Therapy Development Institute (cc-TDI) proudly announces its partnership with Team KOODAC (Knock Out Oncogenic Drivers and Curing Childhood Cancer), a global interdisciplinary
We are excited to update you on entinostat, a therapy that’s traveled through cc-TDI’s development pipeline in the fight against rhabdomyosarcoma (RMS). Entinostat is a breast
The cc-TDI Youth Art & Writing Contest invites K–12 students to showcase their creativity while joining the fight against childhood cancer. Whether through visual art
To Donate to this cause, please click here Throughout Maya’s brave journey, our family found both hope and guidance in cc-TDI’s work, making this cause
This year marks 10 years of innovation and progress at cc-TDI, and we’re proud to reflect on the milestone we’ve reached—because of you. Despite a
We’re celebrating 10 years of impact at cc-TDI! Thanks to your partnership, we’ve translated two drugs into three national and international clinical trials, published 68
The Children’s Cancer Therapy Development Institute (cc-TDI) is proud to announce a new publication, DNA methylation patterns are influenced by Pax3::Foxo1 expression and developmental lineage
This holiday season, we recognize the promise that our research holds for childhood cancer heroes and their families. And at cc-TDI, the parent partnership is
Be part of our team, uncovering how childhood cancers work – and helping find the treatments that could go to clinical trials to improve outcomes.
The Children’s Cancer Therapy Development Institute (cc-TDI) has been awarded $222,120 by the Megan’s Mission Foundation to advance three clinical research initiatives focused on Rhabdomyosarcoma
This month, we invite you to join us in supporting pioneering research at cc-TDI, which has served as a beacon of hope for families like ours. Our
In a groundbreaking study, Entinostat as a combinatorial therapeutic for rhabdomyosarcoma, published earlier this week in Scientific Reports, researchers with the Children’s Cancer Therapy Development
The Children’s Cancer Therapy Development Institute (cc-TDI) is delighted to welcome former Intel Executive, Claire Newman, as their new Executive Director on July 1st. Claire
The Hundt Strong golf outing began in 2017 as a way to support Billy Hundt during his extensive treatment for rhabdomyosarcoma (RMS). From that very
On Monday, May 13th, joined by dear supporters and friends, cc-TDI virtually celebrated the one-year anniversary of our new laboratory. Thanks to incredible support over
In March the Children’s Cancer Therapy Development Institute (cc-TDI) announced its partnership with Team KOODAC (Knock Out Oncogenic Drivers and Curing Childhood Cancer), a global
We are thrilled to present the 2023 inaugural Impact Report for the Children’s Cancer Therapy Development Institute (cc-TDI), a testament to our joint commitment to advancing childhood
We proudly announce our global Artificial Intelligence (AI) collaboration with Atomwise, resulting in a new publication in the journal Scientific Reports. The paper, “AI is
In a significant stride towards advancing pediatric cancer research, we are thrilled to announce that the state of Oregon has allocated a generous $1 million
The Children’s Cancer Therapy Development Institute (cc-TDI) proudly announces its partnership with Team KOODAC (Knock Out Oncogenic Drivers and Curing Childhood Cancer), a global interdisciplinary
We are excited to update you on entinostat, a therapy that’s traveled through cc-TDI’s development pipeline in the fight against rhabdomyosarcoma (RMS). Entinostat is a breast
EIN: 46-5759569
cc-TDI is a qualified 501(c)(3) charitable organization registered with the IRS
(consult with a CPA regarding specific tax implications)
Copyright 2024 – Children’s Cancer Therapy Development Institute